ClinicalTrials.gg
CompletedNCT01495338Updated Sep 14, 2017

A Comparison of the Safety and Comfort of AC-170

A Phase 1 interventional study of AC-170 0.17% and AC-170 0.24% (Formulation 1) in Normal Ocular Health, sponsored by Aciex Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-09-14.

Sponsored by Aciex Therapeutics, Inc. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and comfort of AC-170 compared to a placebo.

02

Conditions studied

  • Normal Ocular Health
03

In context

Lead sponsor

Aciex Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able and willing to avoid the use of ocular medications or topical ocular preparations within protocol specific time period.

Exclusion criteria

Exclusion Criteria:

  • Known or sensitivities to the study medication or its components.
  • Any ocular condition that, in the opinion of the investigator, could affect the subjects safety or trial parameters.
  • Use of disallowed medications during the period indicated prior to the study enrollment or during the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    AC-170 0.17%

    Drug: AC-170 0.17%

  • Experimental
    AC-170 0.24% (Formulation 1)

    Drug: AC-170 0.24% (Formulation 1)

  • Experimental
    AC-170 0.24% (Formulation 2)

    Drug: AC-170 0.24% (Formulation 2)

  • Placebo comparator
    Olopatadine hydrochloride 0.2%/Tears Naturale II

    Drug: Olopatadine hydrochloride 0.2%/Tears Naturale II

Interventions

06

What researchers measure

Primary outcomes

  1. Drop Comfort Score

    drop comfort on 0-10 scale

    Time frame: during 3 minute period

07

Study locations

1 site
  • Andover Eye Associates
    Andover, Massachusetts 01810, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 15, 2011
First posted
Dec 20, 2011
Start
Dec 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Sep 14, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01495338
Lead sponsor
Aciex Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 20, 2011
Start date
Dec 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Sep 14, 2017

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetirizine

Start the discussion